Covidien’s Mallinckrodt Baker signs licensing agreement with Rubicon Research

Following the launch of its PanExcea performance excipient, Mallinckrodt Baker is teaming with Rubicon Research to expand its performance excipient platform. The two companies will develop and launch additional products under the PanExcea brand through 2009.

Under the agreement, Rubicon Research will provide technology development and formulation expertise to Mallinckrodt Baker.

Pratibha Pilgaonkar, CEO of Rubicon Research, said: “This collaboration with Mallinckrodt Baker enhances our position as a global comprehensive solution provider for diverse drug development challenges.”